A. King

Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes

S. Halford, U. Şahin, D. Jodrell, 2016, Clinical Cancer Research.

Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunological and Clinical Outcomes Running Title: Anti-CEA DNA Fusion Vaccination

S. Halford, U. Şahin, D. Jodrell, 2016 .

DNA vaccines to attack cancer

C. Ottensmeier, J. Rice, F. Stevenson, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Vaccine Therapy in NHL: Future Promises and Current Limitations

C. Ottensmeier, F. Stevenson, Andrew King, 2003, Leukemia & lymphoma.

MO212: Updated Interim Results of A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of BION-1301 in Patients With IGA Nephropathy

J. Barratt, B. Schwartz, B. Sorensen, 2022, Nephrology, Dialysis and Transplantation.

High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

N. Potter, C. Craddock, N. Russell, 2022, Blood.

Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunological and Clinical Outcomes

U. Şahin, C. Ottensmeier, T. Weinschenk, 2016 .